Navigation Links
Memory Pharmaceuticals to Announce First Quarter 2008 Results on Wednesday, May 14, 2008

MONTVALE, N.J., May 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced today that it will report its first quarter 2008 financial results on Wednesday, May 14, 2008, before the U.S. financial markets open. Management will provide a Company update and discuss the first quarter results during a conference call the same day, at 9:00 a.m. EST.

Investors and other interested parties may access the call as follows:

Date: Wednesday, May 14, 2008

Time: 9:00 a.m. EDT

Telephone (U.S.): 866.356.4441

Telephone (international): 617.597.5396

Participant Passcode: 80809977

Webcast: under the

"Investors" section

An audio replay of the conference call will be available from 11:00 a.m. EDT on Wednesday, May 14, 2008, until Wednesday, May 21, 2008. To access the replay, please dial 888.286.8010 (U.S.) or 617.801.6888 (international) and enter pass code number 14991737. An audio replay of the conference call will also be available under the "Investors" section of the Company's website during the same period.

About Memory Pharmaceuticals

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Memory in artificial atoms
2. Memory Pharmaceuticals Receives Nasdaq Notification
3. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
4. Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs
5. Memory Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Results on Thursday, March 6, 2008
6. Memory Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
8. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
9. Memory Pharmaceuticals to Announce Third Quarter Results on Thursday, November 8, 2007
10. ASU researchers improve memory devices using nanotech
11. BioMedical Enterprises, Inc. (BME) Receives FDA Clearance for Spine Use of Its Memory Metal Implants
Post Your Comments:
(Date:12/1/2015)... 1, 2015  Symic, a clinical-stage biotherapeutics company developing ... (ECM), today announced that it has secured $25 million ... pipeline, including its lead candidates SB-030 and SB-061. The ... participation by all existing major investors, as well as ... capital raised by Symic to over $43 million since ...
(Date:12/1/2015)... Dallas, Texas (PRWEB) , ... December 01, 2015 ... ... its annual global meeting this month and Dr. J. Kyle Mathews ... worldwide.” This includes the new single site hysterectomy. , An experienced urogynecologist, founder ...
(Date:11/30/2015)... ... 2015 , ... Global Stem Cells Group Chile ... Central America and abroad for the first Iberoamerican Convention on Aesthetic Medicine, Cosmetology ... Testart will present and discuss new trends in anti-aging stem cell treatments, regenerative ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care ... in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. ... stem cell medicine to patients from around the world. , The clinics will be headed ...
Breaking Biology Technology:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
Breaking Biology News(10 mins):